Category - Developments

Developments

Opsens gets FDA clearance to market diastolic pressure algorithm

Opsens (TSX:OPS; OTCQX:OPSSF) received 510(k) clearance from the FDA to market its diastolic pressure ratio (dPR) algorithm. The algorithm is designed to be used with Opsens’ OptoWire, a coronary guide wire used for...

December 19, 2019

Developments

Independent research on Helius’ PoNS treatment for TBI published

Independent research conducted at the University of Wisconsin-Madison on Helius Medical Technologies’ (NASDAQ:HSDT; TSX:HSM) translingual neurostimulation for the treatment of chronic symptoms due to mild-to-moderate...

December 19, 2019

Developments

Kane Biotech fulfills first major animal oral care product order from China

Kane Biotech (TSX-V:KNE) fulfilled its first major order, for $125,000 in bluestem pet oral care products, to its exclusive Chinese distribution partner, Eetoys Pet Products. Kane announced the exclusive distribution...

December 17, 2019

Developments

Avadel Pharma completes enrollment in Phase 3 narcolepsy trial

Avadel Pharmaceuticals (NASDAQ:AVDL) completed enrollment in its pivotal trial assessing FT218 for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The Phase 3 study, called REST-ON, enrolled 212...

December 17, 2019

Developments

Pacira reports positive Phase 3 results for long-acting local analgesic in pediatric patients

Pacira BioSciences (NASDAQ:PCRX) reported positive results from its Phase 3 study of EXPAREL in pediatric patients undergoing spinal or cardiac surgeries. EXPAREL is a non-opioid, single-dose, long-acting local...

December 17, 2019

Developments

Eiger initiates rolling NDA for progeria drug candidate

Eiger BioPharmaceuticals (NASDAQ:EIGR) initiated a rolling NDA submission to the FDA for lonafarnib for the treatment of Hutchinson-Gilford progeria syndrome and progeroid laminopathies. Progeria is an extremely rare...

December 17, 2019

Developments

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kamada (NASDAQ, TASE:KMDA) randomized the first patient in a pivotal clinical trial evaluating its inhaled alpha-1 antitrypsin (AAT) therapy for the treatment of alpha-1 antitrypsin deficiency (AATD). AATD is an...

December 17, 2019

Developments

Kane Biotech launches anti-biofilm shampoo consumer product test

Kane Biotech (TSX-V:KNE) launched a consumer product test to evaluate the efficacy of its new shampoo on dermatitis and dandruff. Research indicates that microbial biofilms may aggravate symptoms associated with...

December 16, 2019

Developments

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

OncoSec Medical (NASDAQ:ONCS) presented interim results from KEYNOTE-890, an ongoing Phase 2 study of its TAVO drug candidate in combination with KEYTRUDA in patients with metastatic, chemotherapy-refractory triple...

December 13, 2019

Developments

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF) presented results of clinical studies with its lead product candidate, Bria-IMT, in combination with immune checkpoint inhibitors in advanced breast cancer at 2019 San...

December 13, 2019

Category - Developments

Opsens gets FDA clearance to market diastolic pressure algorithm

Independent research on Helius’ PoNS treatment for TBI published

Kane Biotech fulfills first major animal oral care product order from China

Avadel Pharma completes enrollment in Phase 3 narcolepsy trial

Pacira reports positive Phase 3 results for long-acting local analgesic in pediatric patients

Eiger initiates rolling NDA for progeria drug candidate

Kamada enrolls first patient in Phase 3 alpha-1 antitrypsin deficiency trial

Kane Biotech launches anti-biofilm shampoo consumer product test

OncoSec presents interim Phase 2 data in metastatic triple negative breast cancer

BriaCell announces clinical data at 2019 San Antonio Breast Cancer Symposium

General

More